The Global Vulvovaginal Candidiasis Treatment Industry is on a trajectory for significant growth, fueled by advancements within the healthcare sector. According to a recent analysis, the market was valued at a substantial US$1.035 billion in 2023. Looking ahead, the market is projected to reach US$1.607 billion by 2033, reflecting a promising Compound Annual Growth Rate (CAGR) of 4.5%.
A serious health concern is the rise in the incidence of vulvovaginal candidiasis, which is a result of an increase in diabetes cases and frequent antibiotic usage among people. Because more research and development efforts are being made in tandem to get accurate diagnoses, it is anticipated that the increase in VVC instances will spur market expansion.
Request a Sample Report Now to get Premium Insights:
https://www.futuremarketinsights.com/reports/sample/rep-gb-15875
The rapid increase in the global disease burden, coupled with escalating demand for better treatment options and an increasing number of hospital-acquired infections, is also propelling the demand for bacterial vulvovaginal candidiasis treatment.
Furthermore, expanding healthcare infrastructure in developing economies, availability of pharmaceutical drugs, and robust technological advancements in the biopharmaceutical industries are all contributing to significant opportunities for vulvovaginal candidiasis treatment over the forecasted period.
Key Takeaways from the Global Vulvovaginal Candidiasis Treatment Industry Study
- As of 2023, the vulvovaginal candidiasis treatment industry was valued at US$ 1035 Million
- From 2023 to 2033, the industry is poised to grow at a 4.5% CAGR
- By 2033, the vulvovaginal candidiasis treatment market is slated to reach a valuation of US$ 1607 Million
- By route of administration, the oral segment accounted for the largest share of 43.2% and is expected to continue this trend over the forecast period.
- China is poised to yield a CAGR of 4.2% to vulvovaginal candidiasis treatment in 2033
“Increasing prevalence of VVC cases and technological advancement in healthcare are expected to radically transform the vulvovaginal candidiasis treatment industry in the coming years,” comments an analyst at FMI.
Global Vulvovaginal Candidiasis Treatment Industry Competitive Landscape
Astellas Pharma Inc., Mycovia Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd., Scynexis, Inc., Grupo Ferrer Internacional S.A., Pfizer, Inc., Cadila Pharmaceuticals, Bayer AG., Bristol-Myers Squibb Company are some of the key companies in the vulvovaginal candidiasis treatment market.
These players are continuously adopting various strategies such as new product launches, facility expansions, mergers, collaborations, partnerships, and acquisitions to increase their revenue share and gain a competitive edge in the market. for instance,
- In October 2022 – Astellas Pharma Inc. and Pantherna Therapeutics GmbH announced that the companies have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation)*.
- In August 2022 – Mycovia Pharmaceuticals, Inc. announced that it will present VIVJOA™ (oteseconazole) capsules in patients with recurrent vulvovaginal candidiasis (RVVC) at the 2022 Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting. VIVJOA is the first and only FDA-approved medication for RVVC indicated to reduce the incidence of RVVC in females with a history of RVVC who are NOT of reproductive potential
- In July 2022 – Mycovia Pharmaceuticals, Inc. announced the U.S. availability of VIVJOA™ (oteseconazole) capsules, an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.
Key Segments Covered in the Global Vulvovaginal Candidiasis Treatment Industry Industry Survey
Global Vulvovaginal Candidiasis Treatment Industry by Drug Class:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
Global Vulvovaginal Candidiasis Treatment Industry by Route of Administration:
- Oral Vulvovaginal Candidiasis Treatment
- Intravenous Vulvovaginal Candidiasis Treatment
- Topical Vulvovaginal Candidiasis Treatment
Global Vulvovaginal Candidiasis Treatment Industry by Distribution Channel:
- Hospital Pharmacy for Vulvovaginal Candidiasis Treatment
- Retail Pharmacy for Vulvovaginal Candidiasis Treatment
- Online Pharmacy for Vulvovaginal Candidiasis Treatment
Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/15875
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
